Teva (TEVA) Wins FDA Approval for First Generic Version of Forest Labs' (FRX) Lexapro for Depression -Bloomberg
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Join SI Premium – FREE
Bloomberg reporting Teva (Nasdaq: TEVA) has just won FDA approval for the first generic version of Forest Lab's (NYSE: FRX) lexapro for depression. The company will have 180 days to exclusively sell the product.
While Teva shares are mostly unchanged, Forest Labs (NYSE: FRX) have given up gains following the headlines.
While Teva shares are mostly unchanged, Forest Labs (NYSE: FRX) have given up gains following the headlines.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NVIDIA (NVDA) in talks to invest in data-center company Cloverleaf Infrastructure - WSJ
- Gossamer Bio raises up to $250M in private placement for PAH drug
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
Create E-mail Alert Related Categories
FDA, Rumors, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
